These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11739162)

  • 1. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
    Khouri IF; Saliba RM; Giralt SA; Lee MS; Okoroji GJ; Hagemeister FB; Korbling M; Younes A; Ippoliti C; Gajewski JL; McLaughlin P; Anderlini P; Donato ML; Cabanillas FF; Champlin RE
    Blood; 2001 Dec; 98(13):3595-9. PubMed ID: 11739162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
    Khouri IF; McLaughlin P; Saliba RM; Hosing C; Korbling M; Lee MS; Medeiros LJ; Fayad L; Samaniego F; Alousi A; Anderlini P; Couriel D; de Lima M; Giralt S; Neelapu SS; Ueno NT; Samuels BI; Hagemeister F; Kwak LW; Champlin RE
    Blood; 2008 Jun; 111(12):5530-6. PubMed ID: 18411419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
    Khouri IF; Lee MS; Saliba RM; Jun G; Fayad L; Younes A; Pro B; Acholonu S; McLaughlin P; Katz RL; Champlin RE
    J Clin Oncol; 2003 Dec; 21(23):4407-12. PubMed ID: 14645431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    Khouri IF; Keating M; Körbling M; Przepiorka D; Anderlini P; O'Brien S; Giralt S; Ippoliti C; von Wolff B; Gajewski J; Donato M; Claxton D; Ueno N; Andersson B; Gee A; Champlin R
    J Clin Oncol; 1998 Aug; 16(8):2817-24. PubMed ID: 9704734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
    Corradini P; Tarella C; Olivieri A; Gianni AM; Voena C; Zallio F; Ladetto M; Falda M; Lucesole M; Dodero A; Ciceri F; Benedetti F; Rambaldi A; Sajeva MR; Tresoldi M; Pileri A; Bordignon C; Bregni M
    Blood; 2002 Jan; 99(1):75-82. PubMed ID: 11756155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation in follicular lymphoma.
    Khouri IF
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
    Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
    Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
    Khouri IF; Lee MS; Saliba RM; Andersson B; Anderlini P; Couriel D; Hosing C; Giralt S; Korbling M; McMannis J; Keating MJ; Champlin RE
    Exp Hematol; 2004 Jan; 32(1):28-35. PubMed ID: 14725898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
    Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.